We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+8.21%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$214M
AUM Growth
+$9.71M
Cap. Flow
-$616K
Cap. Flow %
-0.29%
Top 10 Hldgs %
6.68%
Holding
490
New
42
Increased
186
Reduced
165
Closed
36

Top Sells

Rank Stock Value
1
OXLC
Oxford Lane Capital
OXLC
+$1.49M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.06M
3
GEN icon
Gen Digital
GEN
+$1.01M
4
ADBE icon
Adobe
ADBE
+$989K
5
STE icon
Steris
STE
+$907K

Sector Composition

Rank Sector Weight
1 Financials 28.16%
2 Healthcare 18.37%
3 Technology 14.33%
4 Industrials 8.16%
5 Consumer Discretionary 6.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
APLT
326
DELISTED
Applied Therapeutics
APLT
$149K 0.07%
17,524
+314
+2% +$1.85K
CNTA
327
DELISTED
Centessa Pharmaceuticals
CNTA
$148K 0.07%
9,285
+169
+2% +$2.07K
CTRA
328
DELISTED
Coterra Energy
CTRA
$145K 0.07%
6,073
-30,303
-83% -$748K
SBSW icon
329
Sibanye-Stillwater
SBSW
$5.93B
$145K 0.07%
35,193
-4,743
-12% -$20.1K
PCVX icon
330
Vaxcyte
PCVX
$7.7B
$142K 0.07%
1,244
+21
+2% +$1.89K
APA icon
331
APA Corp
APA
$12.8B
$141K 0.07%
5,770
+407
+8% +$11.4K
DVN icon
332
Devon Energy
DVN
$50.9B
$139K 0.06%
3,550
-186
-5% -$8.19K
BHVN icon
333
Biohaven
BHVN
$2.05B
$138K 0.06%
2,760
+50
+2% +$1.95K
ACLX
334
DELISTED
Arcellx
ACLX
$138K 0.06%
1,651
+28
+2% +$1.86K
EWTX icon
335
Edgewise Therapeutics
EWTX
$4.29B
$137K 0.06%
5,145
+91
+2% +$1.81K
FLNA
336
Filana Therapeutics
FLNA
$42.3M
$136K 0.06%
4,634
+83
+2% +$1.91K
NCDL icon
337
Nuveen Churchill Direct Lending
NCDL
$622M
$135K 0.06%
+7,737
New +$135K
BRY
338
DELISTED
Berry Corp
BRY
$134K 0.06%
26,127
+2,940
+13% +$18K
OVV icon
339
Ovintiv
OVV
$16.9B
$134K 0.06%
3,503
-26
-0.7% -$1.12K
PRAX icon
340
Praxis Precision Medicines
PRAX
$8.1B
$132K 0.06%
2,297
+37
+2% +$2K
VRN
341
DELISTED
Veren
VRN
$131K 0.06%
21,374
-1,579
-7% -$11.3K
ANAB icon
342
AnaptysBio
ANAB
$1.5B
$127K 0.06%
3,797
+64
+2% +$2.19K
ZYME icon
343
Zymeworks
ZYME
$1.63B
$127K 0.06%
10,114
+177
+2% +$1.93K
APGE icon
344
Apogee Therapeutics
APGE
$10.1B
$126K 0.06%
2,138
+39
+2% +$1.87K
KYMR icon
345
Kymera Therapeutics
KYMR
$8.66B
$125K 0.06%
2,640
+44
+2% +$1.94K
PTEN icon
346
Patterson-UTI
PTEN
$3.53B
$125K 0.06%
16,313
+860
+6% +$7.92K
NRIX icon
347
Nurix Therapeutics
NRIX
$2.44B
$124K 0.06%
5,512
+101
+2% +$2.29K
ORIC icon
348
Oric Pharmaceuticals
ORIC
$1.17B
$123K 0.06%
11,997
+210
+2% +$2.08K
NMRA icon
349
Neumora Therapeutics
NMRA
$304M
$122K 0.06%
9,261
+163
+2% +$1.9K
DNLI icon
350
Denali Therapeutics
DNLI
$3.78B
$121K 0.06%
4,164
+72
+2% +$1.78K

Similar funds

Virtus ETF Advisers's Q3 2024 Portfolio in Review

As of Q3 2024, Virtus ETF Advisers held 490 positions worth $214M, up 4.8% from $204M the previous quarter. Its ten largest holdings account for 6.7% of the portfolio.

Virtus ETF Advisers's Q3 2024 filing shows 42 new, 186 increased, 165 reduced and 36 closed positions. Its largest new stake was OFS Credit Co: 278,579 shares worth $2.06M. The largest sale was Oxford Lane Capital, an estimated $1.49M.

By sector, the portfolio is most concentrated in Financials at 28% of assets, up from 27% a quarter earlier, followed by Healthcare and Technology.

  • Virtus ETF Advisers's largest Q3 2024 buy was OFS Credit Co: 278,579 shares worth $2.06M.
  • Virtus ETF Advisers added most to Public Storage in Q3 2024, an estimated $927K increase.
  • Virtus ETF Advisers's biggest Q3 2024 reduction was Regeneron Pharmaceuticals, cutting an estimated $1.06M.
  • Virtus ETF Advisers fully exited Oxford Lane Capital in Q3 2024, selling an estimated $1.49M.
  • Virtus ETF Advisers's ten largest holdings make up 6.7% of its $214M portfolio in Q3 2024.
  • Virtus ETF Advisers opened 42 new positions and closed 36 in Q3 2024.
  • Virtus ETF Advisers's portfolio value rose 4.8% quarter-over-quarter to $214M.

Based on Virtus ETF Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.